IP Verse

Teva Pharmaceuticals International Gmbh V. Bendarx Usa - 1:23-cv-00490

Explore the details of the Teva Pharmaceuticals International Gmbh V. Bendarx Usa case under case number 1:23-cv-00490 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00490
Filing Date
May 4, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Cephalon, LLC -
Teva Pharmaceuticals International GmbH -
BendaRx USA -
Eagle Pharmaceuticals, Inc. -

Patents Involved

Patents not found - set an alert to get notified when patents are added.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Sep 20, 2024ORAL ORDER: Having reviewed the parties' Joint Claim Construction Chart, and it appearing that the parties did not identify any claim construction disputes that need to be resolved by the Court prior to trial, IT IS HEREBY ORDERED that the parties' proposed constructions (D.I. 73 at 5) are ADOPTED and the Markman hearing scheduled for October 23, 2024, is CANCELLED. Ordered by Judge Jennifer L. Hall on 9/20/2024. (ceg) (Entered: 09/20/2024)PACER Document
Oct 10, 2024Pro Hac Vice Fee - Credit Card Payment received for Rhochelle Krawetz. ( re 88 MOTION for Pro Hac Vice Appearance of Attorney Rhochelle Krawetz )( Payment of $ 50, receipt number ADEDC-4521102).(DiBenedetto, Emily) (Entered: 10/10/2024)PACER Document
Oct 10, 2024SO ORDERED, re 88 Motion for Pro Hac Vice Appearance of Attorney Rhochelle Krawetz filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. Ordered by Judge Jennifer L. Hall on 10/10/2024. (ceg)PACER Document
Oct 17, 2024Pro Hac Vice Attorney Rhochelle Krawetz for Cephalon, LLC and Teva Pharmaceuticals International GmbH added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (cdd)PACER Document
Jan 6, 2025[SEALED] STIPULATION of Dismissal Regarding the '270 Patent, '863 Patent, '756 Patent and the '350 Patent by Teva Pharmaceuticals International GmbH, Cephalon, LLC. (Hoeschen, Nathan) (Entered: 01/06/2025)PACER Document
Jan 7, 2025[SEALED] SO ORDERED, re 96 Stipulation of Dismissal Regarding the '270 Patent, '863 Patent, '756 Patent and the '350 Patent. Signed by Judge Jennifer L. Hall on 1/7/2025.(*This order has been emailed to local counsel). (ceg) (Entered: 01/07/2025)PACER Document
Jan 13, 2025REDACTED VERSION of 96 Stipulation of Dismissal by Teva Pharmaceuticals International GmbH, Cephalon, LLC. (Hoeschen, Nathan) (Entered: 01/13/2025)PACER Document
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Feb 23, 2024AMENDED COMPLAINT against BendaRx USA- filed by Cephalon, LLC, Teva Pharmaceuticals International GmbH. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I)(DiBenedetto, Emily) (Entered: 02/23/2024)Attachment
Aug 22, 2023NOTICE of Subsequent Authority regarding BendaRx Corp.'s Motions to Dismiss by Cephalon, LLC, Teva Pharmaceuticals International GmbH re (12 in 1:23-cv-00490-CFC) MOTION to Dismiss for Failure to State a Claim, (10 in 1:23-cv-00633-CFC) MOTION to Dismiss for Failure to State a Claim (Attachments: # 1 Exhibit 1)(Hoeschen, Nathan) (Entered: 08/22/2023)Attachment